SAG-101

N/A

Report date: 2023/10/17 16:47:31

Base Information

Drug NameSAG-101

Drug Alias NameAdNuPARmE1A viral therapy (Viroshield, pancreatic ductal adenocarcinoma), Sagetis Biotechoncolytic adenovirus therapy expressing oligopeptide end-modified poly(beta-amino ester) polymers (Viroshield, pancreatic ductal adenocarcinoma), Sagetis BiotechPolymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma., Sagetis BiotechSAG-101

ClassificationBiologics > Oncolytic virus

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsPancreatic Intraductal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSagetis Biotech SL

China Registration ClassN/A

Develop Information

Active CompaniesSagetis Biotech SL

Inactive CompaniesN/A

Active IndicationsPancreatic Intraductal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A